AMAG Pharmaceuticals, Inc. to Host Conference Call on February 6, 2014 at 8:00 a.m. ET to Discuss Financial Results for the

AMAG Pharmaceuticals, Inc. to Host Conference Call on February 6, 2014 at 8:00
a.m. ET to Discuss Financial Results for the Quarter and Year Ended 2013

WALTHAM, Mass., Feb. 4, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced it will report unaudited consolidated financial
results for the fourth quarter and year ended December 31, 2013 before the
U.S. financial markets open on Thursday, February 6, 2014. The announcement
will be followed by a conference call and webcast with slides at 8:00 a.m. ET
during which management will discuss the company's financial results,
commercial progress and development programs.

To access the conference call via telephone, please dial (877) 412-6083 from
the United States or (702) 495-1202 for international access. A telephone
replay will be available from approximately 11:00 a.m. ET on February 6, 2014
through midnight on February 13, 2014. To access a replay of the conference
call, dial (855) 859-2056 from the United States or (404) 537-3406 for
international access. The pass code for the live call and the replay is
58720931.

The call will be webcast with slides and accessible through the Investors
section of the company's website at www.amagpharma.com. The webcast replay
will be available from approximately 11:00a.m. ET on February 6, 2014 through
midnight March 7, 2014.

About AMAG

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets
Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound Rinse in
the United States. Along with driving organic growth of its products, AMAG
intends to expand its portfolio with additional commercial-stage specialty
products. The company is seeking complementary products that leverage the
company's commercial footprint and focus on hematology and oncology centers
and hospital infusion centers. For additional company information, please
visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc.MuGard® is a registered trademark of Access
Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals, Inc. Contact:
         Amy Sullivan, 617-498-3303

AMAG Pharmaceuticals logo
 
Press spacebar to pause and continue. Press esc to stop.